Sandro Sorbi

The paper identifies ERP biomarkers distinguishing subjective cognitive decline, MCI, and healthy controls during a sustained visual attention task, showing condition-specific dynamics and task performance correlations.

The paper analyzes exome data from 22,319 individuals to identify rare CNVs and 22q11.21 dosage as risk factors for Alzheimer's disease.

The paper uses proteomic analysis of patient iPSC-derived brain cells and post-mortem hippocampal tissue to study early AD pathogenesis and prion-like spread.

The paper identifies high-priority missense variants in SORL1 associated with increased Alzheimer's Disease risk and earlier onset, suggesting clinical counseling considerations for carriers.

This study investigates the association between cerebellar and subcortical atrophy and neuropsychiatric symptoms in genetic frontotemporal dementia, finding significant differences across genetic mutations.

The paper identifies rare damaging variants in ATP8B4 and ABCA1 as novel risk factors for Alzheimer's Disease using exome sequencing data from 32,558 individuals.

This study shows that atrophy patterns in bvFTD are shaped by both global brain network structure and local transcriptomic vulnerability from disease-related genes.

The paper investigates the relationship between gene expression and brain atrophy in genetic frontotemporal dementia, finding correlations between atrophy patterns and specific gene sets related to vascular, glial, and neuronal functions.

The paper develops a random forest classifier to diagnose behavioral variant frontotemporal dementia using MRI and cognitive scores, achieving high accuracy in both training and validation cohorts.

This paper introduces SuStaIn, a machine learning method that identifies disease subtypes and their temporal progression from cross-sectional data, improving prediction of diagnostic conversion in neurodegenerative diseases.

The paper detects pre-symptomatic shape changes in the thalamus using spatiotemporal analysis of MRI scans from the GENFI study, finding differences five years before symptoms appear.